Stato dell arte del. Antonio ROSSI, MD. Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY
|
|
- Shanon Ford
- 6 years ago
- Views:
Transcription
1 Stato dell arte del trattamento del microcitoma Antonio ROSSI, MD Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY
2 Truly has become small. Last session/day in all meetings One chemo talk, 1 RT talk, 1 surgery (?) Decreasing incidence 22% to 15% As many patients with ihmesothelioma Only 2 lines of therapy Few patients considered for 2 nd line Small on the budget. Decreasing research.small returns Decreasing publications ASCO one
3
4 SCLC: C: Staging g (VALG) Limited stage disease Confined to one hemithorax and Stadio regional lymph nodes, including 80% ipsilateral supraclavicular lymph 70% nodes 60% 50% 40% Stadio Extensive stage disease Extend beyond one hemitorax and/or malignant pleural effusion 30% 20% 10% 0% LS-SCLC ES-SCLC Patel AM, et al. Mayo Clin Proc 1993; 68:
5 IASLC Lung Cancer Database: SCLC Small Cell LungCancer: Stage Distribution by Continent, 13,290 Cases Limited 1500 Extensive Percent of total small cell cases contributed Europe Australia N. America Asia (58%) (6%) (34%) (2%) TNM Only Shepherd F, et al. J Thorac Oncol 2007; 2:
6 TNM7: Small Cell Lung Cancer Shepherd F, et al. J Thorac Oncol 2007; 2: TNM6 TNM7 Survival by clinical sixth edition of TNM, and IASLC proposed p TNM stage
7
8
9 Historical surgical options in SCLC It is a lung cancer ( 50s 60s) Do not touch, it is a SCLC! ( 70s early 80s) Renewed interest ( 90s) No randomized trials!
10 8,791 patients with L SCLC, 915 (10.4%) had undergone surgical resection Stage % of pts Median survival (months) I vs II vs III vs (p = ) ASCO 2011, abstr. 7021
11 5 y S 31% 5 y S 3.08%
12 Primary surgery in SCLC It is advised in very limited disease (Stage I: T 1 2,N 0,M 0 ) Adjuvant chemotherapy should follow the surgery Postoperative radiotherapy could be advised only when a nonradical resection was accomplished? Problems to perform a randomized trial: Little number of patients (LD stage I:5%) Accurate staging (Mediastinoscopy)
13
14 SCLC: treatment of limited disease Chemotherapy is the back boneof of therapy Radiation adds about 5% to survival Concurrent therapy increases toxicity compared to sequential
15
16 Studies using Cis based CT had a significant advantage in OS favoring early RT Studies using non Cis based CT had no significant difference in OS A small but significant improvement in 2 yrs OS for early vslate lt RT A greater difference was evident for hyperfractionated RT and Cis based dct Two year overall survival riskio ratio forest plot for early vs. late thoracic radiation therapy Fried DB, J Clin Oncol 2004; 22:
17 Timing of Radiotherapy Looked at time of starting any therapy and end of radiotherapy (SER) Significantly ifi higher h 5 yr survival rate in shorter SER arms (RR = 0.62 p=0.0003) 1.83% decreased survival for each week added to time from the shortest SER De Ruysscher et al JCO 2006
18 Timing of Radiotherapy Differences ee in chemotherapy e compliance between arms within studies mostly explains the heterogeneity of the effect of early radiotherapy on survival Benefit of early radiotherapy in terms of 5 yr survival only in trials where chemotherapy compliance is similar in both arms De Ruysscher et al WCLC 2011
19 The primary end point was complete response rate: early 36% versus late 38% The primary end point was complete response rate: early 36% versus late 38% Neutropenic fever occurred more commonly in the early TRT arm than the late TRT arm (21.6% versus 10.2%; p = 0.02)
20 LD SCLC At what time to combine CT and RT A substantial proportion of patients with LD SCLC present with bulky tumors that wouldrequire largeradiationtargetradiation target volumeswith concomitantincreasesincreases in acute or chronic toxic effects. The complexity of administering TRT concurrently with the first cycle of chemotherapy The complexity of administering TRT concurrently with the first cycle of chemotherapy could result in some delay in treatment initiation.
21 all Cell age Sma g Cancer mited Sta Lung Lim CONVERT study Once daily Thoracic Irradiation D1 D3 D22 D24 D43 D45 D64 D66 rsd, RT 66Gy/45D/33F PR,CR PCI Registration Randomisation PS 0 2 No age limit D1 D3 Twice daily Thoracic Irradiation D22 D24 D43 D45 D64 D66 RT 45Gy/19D/30F Restage Chemotherapy Radiotherapy If<SD No PCI OD XRT C O N V E R T BD
22 Intergroup study CALGB RTOG Gy BID (1.5 Gy/fx) 3 weeks from day 1 Control TRT arm Limited SCLC PS 0 1 PE X 4 PCI Cycle 1 or 2 TRT 61.2 Gy Concomitant Boost (QD 1.8 Gy/fx for 16 days than BID 1.8 Gy /fx for 9 days) 5 weeks from day 1 Re assess 70 Gy QD (2.0 Gy/fx) 7 weeks from day 1 Primary endpoints = OS VS. Experimental TRT arm
23
24 ED SCLC: 1 st Line Therapy The combination of platinum and etoposide (PE) became the standard of care for SCLC in the 1990s when this regimen was shown to be as effective as cyclophosphamide anthracycline vincristine anthracycline based combinations such as CAV, but with less toxicities PE results in ORR 60 80% (10 20% CR), median OS 8 10 months, 1 year S 35%, 2 year S 5 10%
25 ED SCLC 1 st Line Therapy Attempts to improve outcomes in first line ED SCLC 1. Addition of a third active agent 2. Increase dose intensity with or without stem cell transplant 3. Platinum compound 4. New chemotherapeutics: h topotecan, ii irinotecan, pemetrexed 5. Maintenance therapy
26 ED SCLC 1 st Line Therapy Attempts to improve outcomes in first line ED SCLC 1. Addition of a third active agent 2. Increase dose intensity with or without stem cell transplant 3. Platinum compound 4. New chemotherapeutics: h topotecan, ii irinotecan, pemetrexed 5. Maintenance therapy
27 ED SCLC Treatment Multidrug Cisplatin + Etoposide Combinations Reference Regimen No. of Pts MST (mo) 1 Yr Survival (%) p Value Loehrer et al, 1995 Mavroudis et al, 2001 Pujol et al, 2001 Niell et al, 2005 EP vs EP + ifosfamide EP vs EP + paclitaxel EP vs EP + epidoxorubicin + cyclophosphamide EP vs EP + paclitaxel Myelosuppression [*] [*] Toxicity related death rate = 9% Addi i f hi d ( ) i EP i ff i (OS) d ll i d Addition of a third (or more) active agent to EP ineffective (OS) and generally associated with toxicity. Outside of a clinical trial setting, this approach has to be discouraged
28 ED SCLC 1 st Line Therapy Attempts to improve outcomes in first line ED SCLC 1. Addition of a third active agent 2. Increase dose intensity with or without stem cell transplant 3. Platinum compound 4. New chemotherapeutics: h topotecan, ii irinotecan, pemetrexed 5. Maintenance therapy
29 Progression Free Survival Overall Survival
30
31 Objective response Overall survival
32 Hemoglobin nadir Leukocyte nadir Platelet nadir
33 ED SCLC 1 st Line Therapy Attempts to improve outcomes in first line ED SCLC 1. Addition of a third active agent 2. Increase dose intensity with or without stem cell transplant 3. Platinum compound 4. New chemotherapeutics: h topotecan, ii irinotecan, pemetrexed 5. Maintenance therapy
34 OVERALL SURVIVAL PROGRESSION FREE SURVIVAL The choice of the platinum compound for first line treatment of patients with SCLC in The choice of the platinum compound for first line treatment of patients with SCLC in clinical practice should take into account the expected toxicity profile, age, the patient s organ function, and the patient s comorbidities
35 ED SCLC 1 st Line Therapy Attempts to improve outcomes in first line ED SCLC 1. Addition of a third active agent 2. Increase dose intensity with or without stem cell transplant 3. Platinum compound 4. New chemotherapeutics: h topotecan, ii irinotecan, pemetrexed 5. Maintenance therapy
36 ED SCLC Treatment Platinum + Etoposide vs. Platinum + Topotecan Author Platinum/etoposide arm Platinum/topotecan arm No.pts ORR TTP OS (%) (wks) (wks) Eckardt, CDDP 80 mg/m 2 d 1 CDDP 60 mg/m 2 d ETO 100 mg/m 2 d 1 3 TOPO os 1.7 mg/m 2 d 1 5 vs. Q3W Q3W Fink, 2012 CDDP 75 mg/m 2 d 5 CDDP 75 mg/m 2 d ETO 100 mg/m 2 d 1 3 TOPO 1.0 mg/m 2 d 1 5 vs. Q3W Q3W Platinum/Topotecan is noninferior to Platinum/Etoposide in efficacy but for the slightly worse toxicity profile it is not a first line standard treatment in this setting
37 ED SCLC Treatment Platinum + Etoposide vs. Platinum + Irinotecan Author Platinum/etoposide arm Platinum/irinotecan arm No.pts ORR (%) PFS (mo) OS (mo) Noda, 2002 CDDP 80 mg/m 2 d 1 CDDP 60 mg/m² d ETO 100 mg/m 2 dd 1 3 Q3W IRI 60mg/m² dd 1, 8, 15 Q4W vs Hanna, 2006 CDDP 60 mg/m 2 d 1 CDDP 30 mg/m² dd 1, ETO 120 mg/m 2 dd 1 3 Q3W IRI 65 mg/m² dd 1, 8 Q3W vs n.r. 9.3 Hermes, 2008 CBDCA AUC 4 d 1 ETO os 120 mg/m 2 dd 1 5 Q3W CBDCA AUC 4 d 1 IRI 175 mg/m² d 1 Q3W 104 vs. 105 n.r. n.r Lara, 2009 CDDP 80 mg/m 2 d 1 ETO 100 mg/m 2 d 1 3 Q3W CDDP 60 mg/m 2 d 1 IRI 60 mg/m² dd 1, 8, 15 Q4W 327 vs Zatloukal, 2010 CDDP 80 mg/m 2 d 1 ETO 100 mg/m 2 d 1 3 Q3W CDDP 80 mg/m 2 d 1 IRI 65 mg/m 2 d 1, 8 Q3W 203 vs Schmittel, 2011 CBDCA AUC 5 d 1 CBDCA AUC 5 d ETO 140 mg/m 2 d 1 3 Q3W IRI 50 mg/m 2 d 1, 8, 15 Q4W vs
38 Pts: 2,027 ORR RR 1.04 ( ) OS HR 0.81 ( ) PFS HR 0.90 ( ) 07) Favours PI Favours PE The significant heterogeneity found may be due to the pharmacogenomic differences between study populations and race, as well as differences in the studied treatment regimens and their pharmacokinetics. An IPD is awaited to confirm these findings
39 Overall Survival Progression Free Survival
40
41 ED SCLC 1 st Line Therapy Attempts to improve outcomes in first line ED SCLC 1. Addition of a third active agent 2. Increase dose intensity with or without stem cell transplant 3. Platinum compound 4. New chemotherapeutics: h topotecan, ii irinotecan, pemetrexed 5. Maintenance therapy
42 ED SCLC: 1 st Line Therapy Mi Maintenance therapy? 21 RCTs (12 CT, 6 IFs, 4 biological agents), 3,688 SCLC patients No statistically significant advantage for maintenance in terms of: OS (HR 0.93, 95% CI ; p = 0.05) or PFS (HR 0.98, 95% CI ; p = 0.63) Survival advantage for OS (p = 0.02) but not for PFS in CT and IFs trials Is this clinically meaningful? Rossi A et al Lung Cancer 2010
43 ED SCLC 1 st Line Therapy Attempts to improve outcomes in first line ED SCLC 1. Addition of a third active agent 2. Increase dose intensity with or without stem cell transplant 3. Platinum compound 4. New chemotherapeutics: h topotecan, ii irinotecan, pemetrexed 5. Maintenance therapy
44 PCI Meta Analysis 7 RCTs with 987 SCLC patients in complete remission RR of death for PCI was 0.84 (95% CI ; p = 0.01) 5.4% survival improvement at 3 years (15.3% no PCI to 20.7% PCI) Decreased cumulative risk of brain metastases by 25.3% (58.6% to 33.3% PCI. P < 0.001) Benefit was also seen in the small number of patients with Extensive Stage Auperin A, N Engl J Med 1999; 341:
45 PCI in ED SCLC Multicenter RCT by EORTC 286 patients with ED SCLC achieving any response to chemotherapy Median OS increased by 1.3 months (5.4 months in no PCI to 6.7 months in PCI; p = 0.003) OS at 1 year increased from 13.3% to 27.1% Decreased symptomatic brain metastases from 41.3% to 16.8% (p < 0.001) Slotman B, N Engl J Med 2007; 357:
46 AIOM guidelines 2013 Algorithm 4: SCLC
47
48 ED SCLC 2 nd Line Therapy Topotecan is approved for 2nd line therapy but response is low and survival is poor Study Phase Regimen No.pts RR (%) MST (wks) von Pawel 2 Oral Topotecan IV Topotecan Eckardt 3 Oral Topotecan IV Topotecan O Brien 3 BSC Topotecan von Pawel 3 CAV Topotecan
49 Phase III 2 nd Line SCLC: ACT 1 Trial Key entry criteria i SCLC Extensive or Limited disease Sensitive or Refractory disease 1 prior chemotherapy regimen ECOG PS 0 1 ZE DOMI RAN Amrubicin 40 mg/m2 day 1 3 Q3W Topotecan 1.5 mg/m 2 day 1 5 Q3W Primary endpoint: Overall Survival Secondary endpoints: ORR, PFS, TTP, QoL, Safety Analyses: Interim (deaths = 294), Final (deaths = 490) Jotte R, et al. ASCO 2011
50 Jotte R, et al. ASCO 2011
51 AIOM guidelines 2013 Algorithm 5: SCLC second line
52 27 October 30 October 2013 Sydney, Australia WCLC 2013
53 SCLC: Targeted Therapies SCLC Sara Pilotto
54 SCLC: State of the Art TNM staging g should be used, particularly to stratify patients with LD SCLC Patient withvery limited SCLC (T1 2N0M0) may beconsidered for surgical resection LD SCLC patient with good performance status shouldbe treated with concurrent PE and thoracic radiotherapy PCIin responders Standard 1st line therapy remains the combination of PE Topotecan is the only drug approved for 2nd line therapy Very limited progress achieved over the last several years
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationSCLC: Developments in systemic treatment
SCLC: Developments in systemic treatment Egbert F. Smit, Dept. Pulmonary Diseases, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands Staging Outline First line treatment Second line treatment
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationTHERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra,
THERAPY OF SMALL-CELL LUNG CANCER Peter Berzinec Specialised Hospital of St Zoerardus Zobor Teaching Base of the Slovak Medical University Nitra, Slovakia Lancet. 1966;2(7471):979-86. First standard treatment:
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationUpdate on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM San Francisco, CA October 23, 2009 Speaker: Bruce E. Johnson, MD Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationSmall Cell Lung Cancer (SCLC): Update in Therapy. Anne Traynor, MD March 1, 2010
Small Cell Lung Cancer (SCLC): Update in Therapy Anne Traynor, MD March 1, 2010 Small Cell Lung Cancer (SCLC) 12% of lung cancer Strongest epi link with smoking Very high growth fraction Propensity for
More informationSmall Cell Lung Cancer What we have now?
Small Cell Lung Cancer What we have now? Chunxue Bai, M.D., Ph.D. Chair, Chinese Alliance against Lung Cancer Shanghai Respiratory Research Institute Department of Pulmonary Medicine Zhongshan Hospital,
More informationRadiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department
Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly
More informationCurrent Approaches for Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Current Approaches for Limited Small Cell Lung Cancer Laurie Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Can we improve or personalize treatment? Limited Histology/molecular
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationPlace de la radiothérapie dans les CBPC métastatiques
Place de la radiothérapie dans les CBPC métastatiques Cecile Le Péchoux, 12 ème Biennale Monégasque de Cancérologie, 2016 IOT Institut d Oncologie Thoracique CBPC metastatique Rapid doubling time, early
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationTreatment of Small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice
More informationTreatment of Stage I-III SCLC
Treatment of Stage I-III SCLC Prof C Faivre-Finn Manchester Lung Cancer Group Manchester Radiation Related Research Group ESMO-The Christie Preceptorship programme on Lung Cancer 3 rd March 2017 @finn_corinne
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationTreatment of LS (Stage I-III) SCLC
Treatment of LS (Stage I-III) SCLC Prof C Faivre-Finn Manchester Lung Cancer Group Manchester Radiation Related Research Group ESMO-The Christie Preceptorship programme on Lung Cancer 9 th March 2018 @finn_corinne
More informationCooperative Group Update - Japan; JCOG & WJOG -
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center
More informationLung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Lung cancer in the elderly D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Incidence and mortality of all cancers and lung cancer in relation to age and gender (US) 120,000
More informationEuropean Studies in Lung Cancer
European Studies in Lung Cancer Paul Baas 12 th International Lung Cancer Conference 2011, Carlsbad, CA S Overview of trials and other European research activities Question S Which country has the highest
More informationCombining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer
Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer Dr Martin Forster MD PhD Clinical Senior Lecturer in Experimental Cancer Medicine Consultant in Medical Oncology UCL
More informationProphylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer
Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Dr Neil Bayman Consultant Clinical Oncology ESMO-Christie Preceptorship Programme in Lung Cancer, March
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationSmall cell lung cancer
Small cell lung cancer Prof C Faivre-Finn Manchester Lung Cancer Group Manchester Radiation Related Research Group 17 th ESO-ESMO Masterclass 25 th March 2018 Objectives Standard systemic treatment in
More informationLung cancer is the most common cause of cancer-related
GUIDELINES Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline Susanna Cheng, MD,* William K. Evans, MD, Denise Stys-Norman, PgDip, Frances A. Shepherd, MD, and
More informationENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA Formigal, 28 de Junio de 2018 CÓMO DEFINÍAMOS EL ESTADIO
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationRecent Advances in Lung Cancer: Updates from ASCO 2016
Recent Advances in Lung Cancer: Updates from ASCO 2016 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/23/2016
More informationSMALL CELL LUNG CANCER Updated June 2018 by Dr. Kirstin Perdrizet (PGY-5 Medical Oncology Resident, University of Toronto)
SMALL CELL LUNG CANCER Updated June 2018 by Dr. Kirstin Perdrizet (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Adrian Sacher (Staff Medical Oncologist, Princess Margaret Cancer
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationSystemic Therapy for Small Cell Lung Cancer Paul A. Bunn, Jr, MD, Dudley Professor, Univ. of Colorado Cancer Center, Aurora, CO, USA
Systemic Therapy for Small Cell Lung Cancer Paul A. Bunn, Jr, MD, Dudley Professor, Univ. of Colorado Cancer Center, Aurora, CO, USA Consultant: Amgen, Allos, AstraZeneca, Abraxis, Bayer, Biodesix, Boehringer-
More informationSmall cell lung cancer (SCLC) accounts for approximately
ORIGINAL ARTICLE A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer Jingwei
More informationManagement of Small Cell Lung Cancer* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER: ACCP GUIDELINES Management of Small Cell Lung Cancer* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) George R. Simon, MD, FCCP; and Andrew
More informationEffect of radiotherapy on the treatment of patients with extensive stage small cell lung cancer
Effect of radiotherapy on the treatment of patients with extensive stage small cell lung cancer C. Wu, T. Wang, J. Wang, B. Qu, H. Wang and Y. Hu Department of Oncology, The General Hospital of the People
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationSMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)
SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Desiree Hao (Staff Medical Oncologist, University of Calgary) and Dr.
More informationSmall Cell Lung Cancer Case Presentations UCSF/UCD Thoracic Oncology Conference
Small Cell Lung Cancer Case Presentations UCSF/UCD Thoracic Oncology Conference Matthew Gubens, MD Heather Wakelee, MD Extensive Stage SCLC Stanford University School of Medicine November 21, 2009 67 yo
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationClinical Management Guideline for Small Cell Lung Cancer
Diagnosis and Staging: Key Points 1. Ensure a CT scan that is
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More information1 Oregon Health & Science University, Portland, OR 2 Stritch School of Medicine, Loyola University Chicago, Chicago, IL
Current treatment practices for limited-stage small cell lung cancer: A survey of US radiation oncologists on the timing of thoracic radiotherapy with chemotherapy Matthew J. Farrell 1, Jehan Yahya 1,
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationMOLECULAR AND CLINICAL ONCOLOGY 2:
MOLECULAR AND CLINICAL ONCOLOGY 2: 805-810 A meta analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationSmall Cell Lung Cancer: How I Treat Extensive Stage Disease
Small Cell Lung Cancer: How I Treat Extensive Stage Disease Primo N. Lara, Jr., MD Professor of Medicine Associate Director for Translational Research Pop Quiz: These deadly creatures are related in what
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationLA CHEMIOTERAPIA DI I LINEA
DECIDERE LA CHEMIOTERAPIA ADIUVANTE E DELLA MALATTIA METASTATICA LA CHEMIOTERAPIA DI I LINEA Michele Reni Department of Medical Oncology IRCCS Ospedale San Raffaele Milan, Italy 1930 1940 1950 1960 1970
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationSmall cell lung cancer:
Bogota, May 1, 2016 1 Small cell lung cancer: Rolf Stahel University Hospital of Zürich 3 Pathobiology of SCLC 1924 Oat cell carcinoma of the mediastinum (Bernard) 1961 Primary lung tumor (Watson) 1967
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationThe Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer
Evidence-based Series # 7-13-3 EDUCATION AND INFORMATION 2013 The Role of Thoracic Radiotherapy as an Adjunct to Standard Chemotherapy in Limited-Stage Small Cell Lung Cancer Members of the Lung Cancer
More informationAdjuvant radiotherapy for completely resected early stage NSCLC
Adjuvant radiotherapy for completely resected early stage NSCLC ESMO Preceptorship on lung Cancer Manchester March 2018 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique
More informationMinesh Mehta, Northwestern University. Chicago, IL
* Minesh Mehta, Northwestern University Chicago, IL Consultant: Adnexus, Bayer, Merck, Tomotherapy Stock Options: Colby, Pharmacyclics, Procertus, Stemina, Tomotherapy Board of Directors: Pharmacyclics
More informationCombining chemotherapy and radiotherapy of the chest
How to combine chemotherapy, targeted agents and radiotherapy in locally advanced NSCLC? Dirk De Ruysscher, MD, PhD Radiation Oncologist Professor of Radiation Oncology Leuven Cancer Institute Department
More informationMultidisciplinary interactive session (MIS) pn2: The optimal treatment in Wilfried Ernst Erich Eberhardt
Multidisciplinary interactive session (MIS) pn2: The optimal treatment in 2012 Wilfried Ernst Erich Eberhardt Department of Medicine (Cancer Res.), University Hospital Essen, West German Cancer Centre,
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationCombined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC
Combined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC George R. Blumenschein, Jr., MD Associate Professor of Medicine Department of Thoracic/Head & Neck Medical Oncology The University
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationThis document is the result of a comprehensive
Small Cell Lung Cancer* George R. Simon, MD, FCCP; and Henry Wagner, MD Among patients with lung cancers, the proportion of those with small cell lung cancer (SCLC) has decreased over the last decade.
More informationSmall cell lung cancer (SCLC) comprises approximately
Original Article Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients Gun Min Kim, MD,* Young Sam Kim, MD, PhD, Young Ae Kang, MD, PhD, Jae-Heon Jeong, MD, Sun
More informationCommon disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,
Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationCécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010
Prophylactic Cranial Irradiation in Lung Cancer Cécile Le Péchoux Department of Radiation Oncology, Institut Gustave Roussy, Villejuif France Amsterdam 2010 Prophylactic cranial irradiation PCI was introduced
More informationMalignant pleural Mesothelioma: A Year In Review
Malignant pleural Mesothelioma: A Year In Review Rabab Gaafar,MD Prof. Medical Oncology NCI Cairo University National Cancer Institute Conference 2015 ASCO news in Mesothelioma Introduction ASCO news second
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationCitation Cancer Management and Research, 2(1
NAOSITE: Nagasaki University's Ac Title Author(s) Efficacy and safety of amrubicin hy small cell lung cancer Ogawara, Daiki; Fukuda, Minoru; Nak Citation Cancer Management and Research, 2(1 Issue Date
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationWorkshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationSMALL CELL LUNG CANCER
Introduction SMALL CELL LUNG CANCER Current Controversies & Update in Management Dr. Zia Hashim October 29,2004 Small cell lung cancer (SCLC) was initially recognized as an entity distinct from other types
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationTreatment for small cell lung cancer, where are we now? a review
Review Article on Small Cell Lung Cancer Treatment for small cell lung cancer, where are we now? a review Gabriela Alvarado-Luna 1 *, Daniela Morales-Espinosa 2,3 * 1 Fundación Clínica, Médica Sur. Puente
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationCasi clinici di integrazione multiprofessionale: NSCLC stadio III. Biagio Ricciuti. Scuola di Specializzazione in Oncologia Medica
Casi clinici di integrazione multiprofessionale: NSCLC stadio III Scuola di Specializzazione in Oncologia Medica Università degli Studi di Perugia Outline Standard treatment Open questions Clinical cases
More informationUPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN
More informationIntraperitoneal chemotherapy: where are we going? A. Gadducci Pisa
Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal Chemotherapy (IP) in advanced ovarian cancer (EOC): Rationale The spread of disease is often limited to the peritoneal
More informationLUNG CANCER. Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology. Best of ASCO, İstanbul
LUNG CANCER Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology Best of ASCO, İstanbul 2012 23.6.2012 Treatment of Metastatic NSCLC EGFR targetted treatments 1st line: EGFR-mutated: Afatinib
More informationLung Cancer: Personalized Approaches to Non-Small Cell and Small Cell Lung Cancer
Lung Cancer: Personalized Approaches to Non-Small Cell and Small Cell Lung Cancer Speaker: Bruce E. Johnson, MD Chief Clinical Research Officer, Dana-Farber Cancer Institute Professor of Medicine, Harvard
More information